Shexiang Baoxin pill in patients with stable coronary artery disease and reduced eGFR: Subgroup analysis of phase IV randomized trial - PubMed
5 days ago
- #Traditional Chinese medicine
- #Chronic kidney disease
- #Coronary artery disease
- Shexiang Baoxin pill (MUSKARDIA) evaluated in stable CAD patients with reduced eGFR.
- Subgroup analysis of phase IV randomized trial (MUST) with 1,354 participants.
- Numerical advantages observed for MUSKARDIA in primary and secondary endpoints.
- Multivariable adjustment confirmed benefits, showing protective trends after 12-14 months.
- No significant differences in adverse events or liver/kidney function indicators.
- Long-term MUSKARDIA may offer cardiovascular protection in this patient group.